Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas (CIK)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01828008 |
|
Recruitment Status : Unknown
Verified January 2013 by Han weidong, Chinese PLA General Hospital.
Recruitment status was: Not yet recruiting
First Posted : April 10, 2013
Last Update Posted : April 10, 2013
|
Sponsor:
Han weidong
Information provided by (Responsible Party):
Han weidong, Chinese PLA General Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Estimated Primary Completion Date : | May 2015 |
| Estimated Study Completion Date : | May 2015 |